You are here: Industry Insights > AstraZeneca

News List

Atacand to be divested to Cheplapharm in Europe worldpharmanews
July 25, 2018
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a presc
AstraZeneca sells Atacand rights to Cheplapharm pharmatimes
July 25, 2018
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
EU approves AZ’ potassium binder for hyperkalaemia pharmatimes
July 20, 2018
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
AZ signs up for access to Compugen’s pipeline pharmatimes
July 19, 2018
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
Priority review for AZ’ hairy cell leukaemia drug pharmatimes
July 18, 2018
US regulators have assigned priority review status to AstraZeneca and MedImmune’s moxetumomab pasudotox, which is being developed as a treatment for hairy cell leukaemia (HCL).
AZ’ Tagrisso offers sustained benefit in lung cancer pharmatimes
July 17, 2018
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
AZ’ lung cancer drug Tagrisso backed for first-line use pharmatimes
July 12, 2018
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
EU approves first-line use of AZ’ Tagrisso in lung cancer pharmatimes
July 10, 2018
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
AZ, Lilly pull plug on Alzheimer’s disease trials pharmatimes
July 10, 2018
Alzheimer’s disease research has taken another hit with the failure of AstraZeneca and Eli Lilly’s experimental (BACE) inhibitor lanabecestat.
AstraZeneca sheds Seroquel rights pharmatimes
July 09, 2018
AstraZeneca has sold off certain rights to its antipsychotics Seroquel and Seroquel XR in certain territories - including the UK – to Luye Pharma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page